ANTABIO is dedicated to the discovery of novel drugs to treat and prevent antibiotic-resistant bacterial infections.

ANTABIO’s novel compounds block the virulence and the drug-resistance mechanisms of pathogenic bacteria by targeting key bacterial pathways.

Incorporated in 2009, the company is based in the life-sciences technopark “Prologue Biotech” in Labège, France.